Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Universitas Sebelas Maret
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- HsCRP
Study Overview
Brief Summary
This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients
Detailed Description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
This study used calcitriol and a placebo, which were similar in shape; researchers and patients did not know who was getting the drug or placebo.
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •COVID-19 patients, hospitalized patients, and patients aged 18-60 years
Exclusion Criteria
- •pregnancy
Arms & Interventions
Control
Placebo 2x1 per day
Intervention: Placebo (Other)
Calcitriol
the treatment group received calcitriol 2x400 iu per day for 5 day
Intervention: Calcitriol (Drug)
Outcomes
Primary Outcomes
HsCRP
Time Frame: Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization
High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation
Secondary Outcomes
No secondary outcomes reported
Investigators
Nurhasan Agung Prabowo
M.D.
Universitas Sebelas Maret